Cultivating healthier communities allows us to support people around the world on their individual paths toward wellness, thereby creating value for society and our business.

At Teva, we help communities get – and stay – healthy – by providing affordable medicines, collaborating with patient groups and other organisations, starting health initiatives and engaging in innovative research.

We’re proud of what we’ve achieved already. Our efforts have had a positive impact on the lives of people and the health of communities.

The efforts we’ve made already to contribute to healthier communities serve as proof points that as a brand, Teva is committed to making a positive social impact. We do this by aligning resources with the expertise and experience of our people to support relevant areas of social need. And we are fully committed to operating as an ethical, enduring business, with the understanding that this is critical to continue bringing value to our organisation and to society.

We deliver health to patients through our:

Portfolio > We are the world’s leading provider of generic medicines. Our expertise in specialty treatments is focused on disorders of the central nervous system, respiratory disease, cancer, and pain. We also supply the pharmaceutical industry with  high-quality active pharmaceutical ingredients (APIs), ingredients in a pharmaceutical drug that are pharmacologically active.

  • Launched approximately 1,000 generics globally
  • Offered 16,000 products and 50,000 SKUs
  • Held top 3 position for generics in 25 markets
  • Supplied 370+ APIs to nearly 1,000 customers in 100 countries

Programs > We engage in programs to support and improve quality of life for patients and their families.

  • Supported 80+ patient educational programs
  • Reached 300,000+ patients in 38 countries through supported programs
  • Covered various therapeutic areas, including multiple sclerosis and cancer

Pipeline > We reimagine, innovate, and co-create health solutions to improve understanding of medicine and reach high-need patients.

  • Invested $1.8B+ USD in research and development, a significant portion supporting patients with no alternative therapy
  • Funded $350,000+ USD in genetic disorder and autism brain mechanism research with Israel’s Bar-Ilan University
  • In collaboration with FHI 360 and Bill & Melinda Gates Foundation, developing an injectable contraceptive for six-month protection

Partnerships > We join forces with peers, stakeholders, and organizations across sectors, leveraging diverse skills and resources to mitigate barriers to access, support patients and their families, and advocate for patients across disease areas.

  • Convened 17 global patient advocacy groups (total membership of 2,000 organizations in 50 disease areas across 170 countries) via Improving Health Global Patient Advocacy Dialogue
  • Sponsored and participated in the inaugural conference of healthcare experts to address leveraging generics and biosimilars to meet unmet patient needs through the Value Added Medicines group of Medicines for Europe, which Teva chairs

Non-Communicable Diseases (NCDs) and Multiple Chronic Conditions.

One of our big focus areas at the moment is addressing the challenge of Non-communicable diseases (NCDs).

NCDs are not passed from person to person. They are typically of a long duration and progress slowly. The most common NCDs include cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and diabetes.

As life expectancy increases, the number of people who eventually develop NCDs continues to grow. Teva is committed to addressing the burden of NCDs and improving patient lives.

Through ongoing conversations with health leaders and patients, we identified an emerging global health challenge directly related to NCDs; that of Multiple chronic conditions.

Multiple chronic conditions (MCC) are characterised by the presence of two or more chronic conditions. These can include chronic diseases—most of which are non-communicable, such as cardiovascular diseases, but also some communicable diseases, such as tuberculosis and human immunodeficiency virus.

MCC magnifies the complexity of treatment, exponentially increases healthcare costs and, most importantly, affects individuals, caregivers, communities, and health systems.

Through multisectoral partnerships, Teva is committed to helping address MCC by supporting design and implementation of evidence-based care programs targeting concrete outcomes. Working together, we have the potential to improve the quality of life for people with MCC and their caregivers while also decreasing health costs to individuals and society. 

Partnering to address antimicrobial resistance with industry leaders

Antimicrobial resistance (AMR) occurs when bacteria and related illnesses become resistant to antibiotics. Without effective antibiotics, infectious diseases can become deadly outbreaks, not just in humans, but also in our global food supply.

Addressing antibiotic effectiveness and understanding how alternative approaches can treat and prevent infections is a top priority. Teva is committed to being a part of the solution.

In 2017, we developed Teva’s Position on Antimicrobial Resistance to formalize our commitment to combating AMR.